ADC Therapeutics | Innovating Science. Inspiring Hope.
ADC Therapeutics is a commercial-stage oncology company pioneering targeted antibody drug conjugate (ADC) therapies, with its FDA-approved ZYNLONTA (loncastuximab tesirine-lpyl) for relapsed or refractory large B-cell lymphoma. The company is advancing its ADC portfolio into earlier lines of hematologic cancers and solid tumors to address significant unmet medical needs.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMay 2020
Jun 2019
Oct 2017
Jan 2016
Jan 2015
Oct 2013
Oct 2013
Create a free account to see which investors have funded this company.
Create Free Account
BridgeBio Pharma is a clinical-stage biopharmaceutical company developing therapies for genetic d...
Clinical-stage biopharmaceutical company developing FcRn inhibitor therapies for IgG-mediated aut...
Global clinical-stage biopharmaceutical company pursuing novel drug development platforms for rar...
Research-based development stage biopharmaceutical company that discovers and develops innovative...
Clinical-stage biopharmaceutical company developing T cell receptor-based adoptive cell therapies...
Global oncology company focused on developing therapies to tackle the toughest challenges in canc...
